Simvastatin-induced myopathy with concomitant use of cyclosporine: Case report

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 12, 2011, Pages 772-777

  Yang, W H ^a   Zeng, Z S ^a   Ren, X W ^a   Li, Y P ^a   Shang, W J ^a   Feng, G W ^a   Zhang, L R ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

Cyclosporine; CYP3A; Drug drug interaction; Myopathy; Renal transplantation; Simvastatin

Indexed keywords

CYCLOSPORIN; CYTOCHROME P450 3A1; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; FLUINDOSTATIN; GENOMIC DNA; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; ORGANIC ANION TRANSPORTER 2; PREDNISONE; SIMVASTATIN;

ADULT; ALLELE SPECIFICITY POLYMERASE CHAIN REACTION; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LABORATORY TEST; LEG PAIN; LUNG INFECTION; MALAISE; MORNING DOSAGE; MUSCLE SPASM; MUSCLE STIFFNESS; MYASTHENIA; MYOPATHY; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION;

CYCLOSPORINE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; FEMALE; GENOTYPE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MIDDLE AGED; MUSCULAR DISEASES; ORGANIC ANION TRANSPORTERS; SIMVASTATIN;

EID: 82655189980     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201623     Document Type: Article

References (19)

1. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F, Gut I, Lathrop M, Collins R; SEARCH Collaborative Group. SLCO1B1 variants and statin-induced myopathy - a genomewide study. N Engl J Med. 2008; 359: 789-799. doi:10.1056/NEJMoa0801936 PubMed
2. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009; 158: 693-705. doi:10.1111/j.1476-5381.2009.00430.x PubMed
3. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA, Ginsburg GS. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol. 2009; 54: 1609-1616. doi:10.1016/j.jacc.2009.04.053 PubMed
4. Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J. 2011 Jan 18. (Epub ahead of print).
5. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011; 63: 157-181. doi:10.1124/pr.110.002857 PubMed
6. Chiba K, Morimoto K. Genetic marker of statin-induced rhabdomyolysis. Yakugaku Zasshi. 2011; 131: 247-253. doi:10.1248/yakushi.131.247 PubMed
7. Hong R, Sequeira W. Rhabdomyolysis in a patient taking simvastatin after addition of cyclosporine therapy. J Clin Rheumatol. 2000; 6: 324-327. doi:10.1097/00124743-200012000-00005 PubMed (Pubitemid 32104202)
8. Launay-Vacher V, Izzedine H, Deray G. Statins'dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patients. Int J Cardiol. 2005; 101: 9-17. doi:10.1016/j.ijcard.2004.04.005 PubMed (Pubitemid 40614730)
9. Wei KK, JIA M, FU Q, Gao Y, Yang WL, Zhang LR. Correlation of genetic polymorphism with statins therapy and hyperlipidemias. Chin J New Drugs Clin Rem. 2008; 27: 570-575.
10. Li YP, Zhang LR, Jia M, Hu XJ. CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women. J Clin Pharmacol. 2011; 51: 181-188. doi:10.1177/0091270010370589 PubMed
11. Couvert P, Chapman MJ, Carrié A. Impact of genetic variation in the SLCO1B1 gene on statin efficacy in low-density lipoprotein cholesterol-lowering therapy. Pharmacogenomics. 2011; 12: 137-139. doi:10.2217/pgs.10.214 PubMed
12. Abd TT, Jacobson TA. Statin-induced myopathy: a review and update. Expert Opin Drug Saf. 2011; 10: 373-387. doi:10.1517/14740338.2011.540568 PubMed
13. Zhu B, Chen GL, Chen XP, He N, Liu ZQ, Jiang CH, Wang D, Zhou HH. Genotype of CYP3AP1 associated with CYP3A activity in Chinese Han population. Acta Pharmacol Sin. 2002; 23: 567-572. PubMed
14. Li D, Zhang GL, Lou YQ, Li Q, Wang X, Bu XY. Genetic polymorphisms in MDR1 and CYP3A5 and MDR1 haplotype in mainland Chinese Han, Uygur and Kazakh ethnic groups. J Clin Pharm Ther. 2007; 32: 89-95. doi:10.1111/j.1365-2710.2007. 00791.x PubMed (Pubitemid 46213944)
15. Eng HS, Mohamed Z, Calne R, Lang CC, Mohd MA, Seet WT, Tan SY. The influence of CYP3A gene polymorphisms on cyclosporine dose requirement in renal allograft recipients. Kidney Int. 2006; 69: 1858-1864. doi:10.1038/sj.ki.5000325 PubMed (Pubitemid 43739216)
16. Wu XC, Li X. Review on effective blood concentration of CsA in renal transplatial patients. Zhongguo Lin Chuang Yao Li Xue Za Zhi. 2000; 20: 173-175.
17. Hu YF, Tu JH, Tan ZR, Liu ZQ, Zhou G, He J, Wang D, Zhou HH. Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects. Xenobiotica. 2007; 37: 315-327. doi:10.1080/00498250601149206 PubMed (Pubitemid 46442598)
18. Gao Y, Zhang LR, Fu Q. CYP3A4*1G polymorphism is associated with lipid-lowering efficacy of atorvastatin but not of simvastatin. Eur J Clin Pharmacol. 2008; 64: 877-882. doi:10.1007/s00228-008-0502-x PubMed
19. Qiu XY, Jiao Z, Zhang M, Zhong LJ, Liang HQ, Ma CL, Zhang L, Zhong MK. Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients. Eur J Clin Pharmacol. 2008; 64: 1069-1084. doi:10.1007/s00228-008-0520-8 PubMed